Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental Arm) (RANDOMET)
Randomized Open-label Non-inferiority Phase 3 Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental Arm)
Sponsor: Assistance Publique Hopitaux De Marseille
This PHASE3 trial investigates Childhood Renal Tumor and is currently actively recruiting participants. Assistance Publique Hopitaux De Marseille leads this study, which shows 5 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
May 2025 — Present [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — May 2025 [monthly]
Not Yet Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Not Yet Recruiting PHASE3
-
Oct 2018 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Assistance Publique Hopitaux De Marseille
- German Society for Pediatric Oncology and Hematology GPOH gGmbH
For direct contact, visit the study record on ClinicalTrials.gov .